Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Sun Pharmaceutical Industries Ltd rose for a third straight session today. The stock is quoting at Rs 1725.7, up 2.56% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.53% on the day, quoting at 25214. The Sensex is at 82662.59, up 0.5%. Sun Pharmaceutical Industries Ltd has added around 2.4% in last one month.
Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has added around 2.68% in last one month and is currently quoting at 22410.35, up 0.98% on the day. The volume in the stock stood at 22.93 lakh shares today, compared to the daily average of 21.38 lakh shares in last one month.
The benchmark July futures contract for the stock is quoting at Rs 1728.3, up 2.38% on the day. Sun Pharmaceutical Industries Ltd is up 9.27% in last one year as compared to a 2.44% gain in NIFTY and a 8.98% gain in the Nifty Pharma index.
The PE of the stock is 94.39 based on TTM earnings ending March 25.
The drug is indicated for the treatment of alopecia areata — a condition in which the immune system attacks hair follicles, leading to hair loss on the scalp as well as other parts of the body.
The pharmaceutical company announced LEQSELVI after entering into a settlement and license agreement with Incyte Corporation.
Incyte had earlier accused Sun Pharma of patent infringement.
Under the terms of agreement, the parties will seek dismissal of the pending LEQSELVI litigation in the United States District Court for the District of New Jersey and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation.
As a part of agreement, Incyte has granted to Sun a limited, non-exclusive license to patents related to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, in the U.S.
Sun will pay to Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and license.
The scrip had advanced 2.71% to end at Rs 1727.70 on the BSE today.
Sun Pharmaceutical Industries announced LEQSELVI™ (deuruxolitinib) 8 mg tablets is now available to healthcare providers and people living with severe alopecia areata in the U.S.
LEQSELVI is indicated for the treatment of adults with severe alopecia areata.
“The launch of LEQSELVI in the U.S. brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them,” said Richard Ascroft, CEO, Sun Pharma North America. “As a company committed to launching new therapeutic options which address the unmet needs of patients, adding LEQSELVI to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community.”
Sun Pharmaceutical Industries announced that further to its intimation dated 10 April 2025, Sun and Incyte Corporation (Incyte) have entered into a settlement and license agreement regarding litigation related to LEQSELVI™ (deuruxolitinib).
As a part of agreement, Incyte has granted to Sun a limited, non-exclusive license to U.S. Patent Nos. 9,662,335 and certain other related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, in the U.S.
Sun will pay to Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and license. Other specific terms of the settlement and license agreement are confidential.